Protocol Ledger

NCT05196035 · Phase III · ACTIVE NOT RECRUITING

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotens

Interventional Phase III clinical trial protocol NCT05196035 sponsored by Bayer in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-28 Enrollment: 219 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05196035
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)219 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05196035
Protocol FieldVerified Registry Value
NCT IdentifierNCT05196035
Consolidated Lead SponsorBayer
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment219 participants (ESTIMATED)
Registered Start Date2022-03-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI